InClinica CEO Speaks at The World Conference on Advanced Treatments & Technologies in Wound Care in the United Kingdom
James Nolan discussed global clinical trial crisis in London
PHILADELPHIA (October 15, 2018) – InClinica, a global, clinical CRO, announced that CEO James Nolan spoke at The World Conference on Advanced Treatments & Technologies in Wound Care on October 15, 2018, in London, U.K.
Nolan’s lecture, titled “The Global Clinical Trial Crisis,” addressed some of the major challenges companies face when conducting clinical trials. He also offered guidance on key approaches companies must have to succeed during clinical trials and the importance of labeling when developing a clinical strategy.
“More clinical trials are being conducted now than ever before, but not all are destined for FDA approval,” said Nolan. “There are a number of essential approaches a CRO must have to successfully conduct a clinical trial. Biopharma companies must be aware of these to avoid wasting years of research on the wrong partner.”
The World Conference on Advanced Treatments & Technologies in Wound Care in the U.K. presents updates in various areas of the wound prevention and care industries. Topics include an overview of current research in wound prevention and care, potential opportunities for transfer of technologies that are still at the research lab phase into medical technologies and products, and technological gaps in prevention, diagnosis and treatment of all wound types. For more information, visit: http://www.attwc2018.com/default.aspx.
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Wayne, PA, US, with other locations in Israel, Malaysia, the U.K., and throughout Europe.